BioAge Labs' BGE-102 Shows Promising Phase 1 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy BIOA?
Source: NASDAQ.COM
- Clinical Trial Success: BioAge Labs' oral NLRP3 inhibitor BGE-102 demonstrated significant reductions in hsCRP, a key inflammation marker, in a Phase 1 study involving obese participants, with 85% and 86% reductions at Day 7 and Day 21 respectively, indicating strong anti-inflammatory potential.
- Safety Profile: BGE-102 was well tolerated across all dose levels, with no serious adverse events or discontinuations reported, establishing a solid foundation for its clinical application and future trials.
- Future Trial Plans: BioAge intends to advance BGE-102 into a Phase 2 dose-ranging proof-of-concept trial in participants at elevated cardiovascular risk in the first half of 2026, with a Phase 3 trial expected to initiate in 2027, further validating its clinical value.
- Market Performance: BIOA's stock has traded between $3.67 and $24.00 over the past year, closing at $18.80 on Monday and rising 10.64% to $20.80 in pre-market trading, reflecting positive market sentiment regarding the drug's prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIOA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIOA
Wall Street analysts forecast BIOA stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 18.460
Low
15.00
Averages
37.00
High
73.00
Current: 18.460
Low
15.00
Averages
37.00
High
73.00
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Leqembi Iqlik PDUFA Date Extended to August 24
- FDA Review Extension: The U.S. FDA has extended the review period for the supplemental Biologics License Application for Leqembi Iqlik by three months, with a new PDUFA date of August 24, 2026, indicating a thorough review process that may impact the drug's market entry timeline.
- Clinical Data Support: Eisai believes that the comprehensive clinical data package evaluating Leqembi strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which could significantly enhance its competitive position upon approval.
- Global Regulatory Confidence: Leqembi has been approved in 53 countries, reflecting broad regulatory confidence in its efficacy as a treatment option for early Alzheimer's disease, which may facilitate future market expansion opportunities.
- Strategic Partnership: BioArctic has maintained a long-term collaboration with Eisai since 2005 for the development of Leqembi, with BioArctic holding commercialization rights in the Nordic region, suggesting a strategic approach to maximize market reach through partnership.
See More
BioAge Labs Announces R&D Day Webcast Featuring BGE-102 Data
- Clinical Data Release: BioAge Labs will host a webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, targeting atherosclerotic cardiovascular disease (ASCVD) and retinal disease, which is expected to enhance investor confidence in the company's R&D progress.
- Expert Participation: The event will feature four leading academic and clinical experts, including Dr. Michael Davidson from the University of Chicago, who will discuss NLRP3 biology and its implications in ASCVD and retinal diseases, thereby increasing public understanding of BGE-102's potential.
- Therapeutic Mechanism Discussion: BioAge's management will elaborate on BGE-102's unique mechanism as an oral NLRP3 inhibitor, emphasizing its application in reducing cardiovascular risk and retinal diseases, potentially offering new treatment options for patients.
- Future Data Expectations: Phase 2 cardiovascular risk proof-of-concept data for BGE-102 are anticipated in H2 2026, with Phase 1b/2a diabetic macular edema proof-of-concept data expected in mid-2027, further validating its clinical value and advancing subsequent R&D efforts.
See More
BioAge Labs' BGE-102 Shows Promising Phase 1 Results
- Clinical Trial Success: BioAge Labs' oral NLRP3 inhibitor BGE-102 demonstrated significant reductions in hsCRP, a key inflammation marker, in a Phase 1 study involving obese participants, with 85% and 86% reductions at Day 7 and Day 21 respectively, indicating strong anti-inflammatory potential.
- Safety Profile: BGE-102 was well tolerated across all dose levels, with no serious adverse events or discontinuations reported, establishing a solid foundation for its clinical application and future trials.
- Future Trial Plans: BioAge intends to advance BGE-102 into a Phase 2 dose-ranging proof-of-concept trial in participants at elevated cardiovascular risk in the first half of 2026, with a Phase 3 trial expected to initiate in 2027, further validating its clinical value.
- Market Performance: BIOA's stock has traded between $3.67 and $24.00 over the past year, closing at $18.80 on Monday and rising 10.64% to $20.80 in pre-market trading, reflecting positive market sentiment regarding the drug's prospects.
See More
BioArctic Publishes 2025 Annual and Sustainability Reports
- Performance Breakthrough: BioArctic achieved record profits in 2025, marking a new phase of growth for the company after over 20 years of development, highlighting significant advancements in Alzheimer's disease treatment.
- Innovative Drug Launch: The company launched Leqembi, the world's first drug proven to slow the progression of Alzheimer's disease, further solidifying its leadership in neurodegenerative disease treatment and expected to drive future revenue growth.
- Sustainability Strategy: BioArctic's Sustainability Report is integrated with the Annual Report to enhance transparency and meet stakeholder expectations, inspired by the European Corporate Sustainability Reporting Directive, demonstrating the company's commitment to sustainable business practices.
- R&D Investment: The company is not only focused on Leqembi but also developing antibodies against Parkinson's disease and ALS, utilizing its proprietary BrainTransporter™ technology to enhance treatment efficacy, showcasing its broad research potential in the biopharmaceutical sector.
See More
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Participation: BioAge Labs will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, with CEO Kristen Fortney scheduled for a 30-minute fireside chat on April 16, showcasing the company's latest advancements in metabolic diseases, which is expected to attract investor interest.
- Product Candidate Progress: The company's lead product candidate, BGE-102, is currently undergoing Phase 1 SAD/MAD clinical trials, with topline data anticipated in the first half of 2026, demonstrating its potential in treating cardiovascular risk and retinal diseases, which could open new market opportunities for BioAge.
- Diverse R&D Directions: In addition to BGE-102, BioAge is developing long-acting injectable and oral small molecule APJ agonists targeting obesity, reflecting the company's diversified strategic approach in the metabolic disease treatment space to meet growing market demands.
- Strengthening Investor Relations: The company will provide live webcast replays on its website, ensuring investors can access relevant information within 30 days, enhancing communication with investors and improving market transparency and trust.
See More
BIOAGE LABS INC: NEEDHAM BEGINS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $50
- Company Overview: BioAgELabs is a company focused on innovative solutions in the biotechnology sector.
- Investment Recommendation: The company has a "Buy" rating with a target price set at $50, indicating strong potential for growth.
See More
Leqembi Iqlik PDUFA Date Extended to August 24
- FDA Review Extension: The U.S. FDA has extended the review period for the supplemental Biologics License Application for Leqembi Iqlik by three months, with a new PDUFA date of August 24, 2026, indicating a thorough review process that may impact the drug's market entry timeline.
- Clinical Data Support: Eisai believes that the comprehensive clinical data package evaluating Leqembi strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which could significantly enhance its competitive position upon approval.
- Global Regulatory Confidence: Leqembi has been approved in 53 countries, reflecting broad regulatory confidence in its efficacy as a treatment option for early Alzheimer's disease, which may facilitate future market expansion opportunities.
- Strategic Partnership: BioArctic has maintained a long-term collaboration with Eisai since 2005 for the development of Leqembi, with BioArctic holding commercialization rights in the Nordic region, suggesting a strategic approach to maximize market reach through partnership.
See More
BioAge Labs Announces R&D Day Webcast Featuring BGE-102 Data
- Clinical Data Release: BioAge Labs will host a webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, targeting atherosclerotic cardiovascular disease (ASCVD) and retinal disease, which is expected to enhance investor confidence in the company's R&D progress.
- Expert Participation: The event will feature four leading academic and clinical experts, including Dr. Michael Davidson from the University of Chicago, who will discuss NLRP3 biology and its implications in ASCVD and retinal diseases, thereby increasing public understanding of BGE-102's potential.
- Therapeutic Mechanism Discussion: BioAge's management will elaborate on BGE-102's unique mechanism as an oral NLRP3 inhibitor, emphasizing its application in reducing cardiovascular risk and retinal diseases, potentially offering new treatment options for patients.
- Future Data Expectations: Phase 2 cardiovascular risk proof-of-concept data for BGE-102 are anticipated in H2 2026, with Phase 1b/2a diabetic macular edema proof-of-concept data expected in mid-2027, further validating its clinical value and advancing subsequent R&D efforts.
See More
BioAge Labs' BGE-102 Shows Promising Phase 1 Results
- Clinical Trial Success: BioAge Labs' oral NLRP3 inhibitor BGE-102 demonstrated significant reductions in hsCRP, a key inflammation marker, in a Phase 1 study involving obese participants, with 85% and 86% reductions at Day 7 and Day 21 respectively, indicating strong anti-inflammatory potential.
- Safety Profile: BGE-102 was well tolerated across all dose levels, with no serious adverse events or discontinuations reported, establishing a solid foundation for its clinical application and future trials.
- Future Trial Plans: BioAge intends to advance BGE-102 into a Phase 2 dose-ranging proof-of-concept trial in participants at elevated cardiovascular risk in the first half of 2026, with a Phase 3 trial expected to initiate in 2027, further validating its clinical value.
- Market Performance: BIOA's stock has traded between $3.67 and $24.00 over the past year, closing at $18.80 on Monday and rising 10.64% to $20.80 in pre-market trading, reflecting positive market sentiment regarding the drug's prospects.
See More
BioArctic Publishes 2025 Annual and Sustainability Reports
- Performance Breakthrough: BioArctic achieved record profits in 2025, marking a new phase of growth for the company after over 20 years of development, highlighting significant advancements in Alzheimer's disease treatment.
- Innovative Drug Launch: The company launched Leqembi, the world's first drug proven to slow the progression of Alzheimer's disease, further solidifying its leadership in neurodegenerative disease treatment and expected to drive future revenue growth.
- Sustainability Strategy: BioArctic's Sustainability Report is integrated with the Annual Report to enhance transparency and meet stakeholder expectations, inspired by the European Corporate Sustainability Reporting Directive, demonstrating the company's commitment to sustainable business practices.
- R&D Investment: The company is not only focused on Leqembi but also developing antibodies against Parkinson's disease and ALS, utilizing its proprietary BrainTransporter™ technology to enhance treatment efficacy, showcasing its broad research potential in the biopharmaceutical sector.
See More
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Participation: BioAge Labs will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, with CEO Kristen Fortney scheduled for a 30-minute fireside chat on April 16, showcasing the company's latest advancements in metabolic diseases, which is expected to attract investor interest.
- Product Candidate Progress: The company's lead product candidate, BGE-102, is currently undergoing Phase 1 SAD/MAD clinical trials, with topline data anticipated in the first half of 2026, demonstrating its potential in treating cardiovascular risk and retinal diseases, which could open new market opportunities for BioAge.
- Diverse R&D Directions: In addition to BGE-102, BioAge is developing long-acting injectable and oral small molecule APJ agonists targeting obesity, reflecting the company's diversified strategic approach in the metabolic disease treatment space to meet growing market demands.
- Strengthening Investor Relations: The company will provide live webcast replays on its website, ensuring investors can access relevant information within 30 days, enhancing communication with investors and improving market transparency and trust.
See More
BIOAGE LABS INC: NEEDHAM BEGINS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $50
- Company Overview: BioAgELabs is a company focused on innovative solutions in the biotechnology sector.
- Investment Recommendation: The company has a "Buy" rating with a target price set at $50, indicating strong potential for growth.
See More
